Corticotropin is a polypeptide hormone produced and secreted by the pituitary gland. Corticotropin acts through the stimulation of cell surface the adrenocorticotropic hormone (ACTH) receptors, which are primarily located on the adrenocortical cells. Corticotropin stimulates the cortex of the adrenal gland and boosts the synthesis of corticosteroids, mainly glucocorticoids but also sex steroids (androgens).
Corticotropin is indicated as monotherapy for the treatment of exacerbations of multiple sclerosis in adults and infantile spasms in infants and children under 2 years of age. Controlled clinical trials have shown Corticotropin to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease. The mechanism of action of Corticotropin in the treatment of infantile spasms is unknown.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ACTHAR Approved UseH.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age; H.P. Acthar Gel is indicated for the treatment of exacerbations of multiple
sclerosis in adults; H.P. Acthar Gel may be used for the following disorders and diseases: rheumatic; collagen; dermatologic; allergic states; ophthalmic; respiratory; and edematous state. Launch Date1950 |
|||
| Primary | ACTHAR Approved UseH.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age; H.P. Acthar Gel is indicated for the treatment of exacerbations of multiple
sclerosis in adults; H.P. Acthar Gel may be used for the following disorders and diseases: rheumatic; collagen; dermatologic; allergic states; ophthalmic; respiratory; and edematous state. Launch Date1950 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The role of ether-a-go-go-related gene K(+) channels in glucocorticoid inhibition of adrenocorticotropin release by rat pituitary cells. | 2009-01-08 |
|
| Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature. | 2009 |
|
| Partial 17alpha-hydroxylase/17,20-lyase deficiency-clinical report of five Chinese 46,XX cases. | 2008-07 |
|
| Long-term weekly ACTH therapy for relapsed West syndrome. | 2008-06 |
|
| Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment-resistant depression: involvement of 5-HT(2A) receptors? | 2008-05 |
|
| Effects of imipramine and bupropion on the duration of immobility of ACTH-treated rats in the forced swim test: involvement of the expression of 5-HT2A receptor mRNA. | 2008-02 |
|
| Sex specific associations between common glucocorticoid receptor gene variants and hypothalamus-pituitary-adrenal axis responses to psychosocial stress. | 2007-10-15 |
|
| Therapeutic efficacy and adverse effects of adrenocorticotropic hormone therapy in west syndrome: differences in dosage of adrenocorticotropic hormone, onset of age, and cause. | 2006-04 |
|
| Aryl hydrocarbon receptor activation impairs cortisol response to stress in rainbow trout by disrupting the rate-limiting steps in steroidogenesis. | 2006-04 |
|
| Repeated electroconvulsive stimuli increase brain-derived neurotrophic factor in ACTH-treated rats. | 2006-01-04 |
|
| Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. | 2005-12-06 |
|
| Nelson's syndrome due to an intracavernous corticotropin-secreting adenoma. | 2004-07-15 |
|
| Inhibition of CYP17 expression by adrenal androgens and transforming growth factor beta in adrenocortical cells. | 2004 |
|
| Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. | 2003-07 |
|
| Paraventricular nucleus administration of calcitonin gene-related peptide inhibits food intake and stimulates the hypothalamo-pituitary-adrenal axis. | 2003-04 |
|
| Effects of chronic 'Binge' cocaine administration on plasma ACTH and corticosterone levels in mice deficient in DARPP-32. | 1999-09 |
|
| Activity of adenosine deaminase in red blood cells of patients suffering from multiple sclerosis treated with adrenocorticotropic hormone. | 1995-11-01 |
|
| Magnetic resonance imaging in infantile spasms: effects of hormonal therapy. | 1992-03-01 |
|
| Infantile spasms in COFS syndrome. | 1991-07-01 |
|
| ACTH and vasopressin responses to insulin-induced hypoglycemia in intact and neurohypophysectomized conscious dogs. | 1991-01 |
|
| A dystonia-like syndrome after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus. | 1988 |
|
| [Long-term prognosis of infantile spasms after standard ACTH treatment in Japan]. | 1986-09 |
|
| Cerebral blood flow and brain shrinkage seen on CT during ACTH therapy. | 1986 |
|
| Administration of ACTH to suckling rats results in hyperkinetic behavior. | 1986 |
|
| Suppressive action of ACTH on growth hormone secretion in patients with infantile spasms. | 1985 |
|
| Acute-onset transient hydrocephalus after suspension of ACTH therapy for infantile spasms: a case report. | 1984-06 |
|
| 'Dystonia'-like postural asymmetry after microinjection of ACTH N-terminal fragments but not after ACTH1-39 in rat brainstem suggests role of neuropeptide mutation in genetic movement disorder. | 1984-02-27 |
|
| Sequential CT studies of 24 children with infantile spasms on ACTH therapy. | 1983-08 |
|
| [Collateral transient behavioural changes during ACTH therapy in infantile generalized epilepsy (author's transl)]. | 1981-03-01 |
|
| Aicardi's syndrome: are corticosteroids teratogens? | 1981-01 |
|
| Transient brain shrinkage in infantile spasms after ACTH treatment. Report of two cases. | 1980-02 |
|
| Cerebral atrophy following ACTH therapy. | 1980-02 |
|
| Reversible cerebral atrophy and corticotrophin. | 1979-07-28 |
|
| Steroid myopathy complicating McArdle's disease. | 1970-02 |
|
| [Neuropsychiatric complications caused by cortisone and ACTH. (Clinico-social considerations)]. | 1968-04-01 |
|
| Some observations on the hazards of corticosteroid therapy in patients with inflammatory bowel disease. | 1967-03-01 |
|
| Complications of corticotropin therapy in multiple sclerosis. | 1966-07-18 |
|
| [SYNDROME OF INTRACRANIAL HYPERTENSION CAUSED BY TREATMENT WITH CORTICOTROPIN]. | 1964-01-31 |
| Substance Class |
Protein
Created
by
admin
on
Edited
Mon Mar 31 20:36:37 GMT 2025
by
admin
on
Mon Mar 31 20:36:37 GMT 2025
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
K0U68Q2TXA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Related Record | Type |
|---|
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 862.1025
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
NDF-RT |
N0000006478
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
LOINC |
14674-6
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
WHO-VATC |
QH01AA01
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
LOINC |
15042-5
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
LOINC |
2141-0
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
NDF-RT |
N0000006478
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
FDA ORPHAN DRUG |
168103
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
FDA ORPHAN DRUG |
399113
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
NDF-RT |
N0000006478
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
LOINC |
6879-1
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
NDF-RT |
N0000006478
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
NDF-RT |
N0000006478
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
LOINC |
2140-2
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
LOINC |
16652-0
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
NDF-RT |
N0000006478
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
LOINC |
66732-9
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
NDF-RT |
N0000175941
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
WHO-ATC |
H01AA01
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
||
|
NDF-RT |
N0000006478
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB01465MIG
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | |||
|
12427-33-7
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | |||
|
DB01285
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | |||
|
K0U68Q2TXA
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | |||
|
3892
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | |||
|
376
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | RxNorm | ||
|
CHEMBL1201610
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | |||
|
Corticotropin
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | |||
|
1366
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | |||
|
4931
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | |||
|
1149004
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | |||
|
3633
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | |||
|
100000091474
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | |||
|
m1395
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | Merck Index | ||
|
K0U68Q2TXA
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | |||
|
C212
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | |||
|
16132265
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY | |||
|
D000324
Created by
admin on Mon Mar 31 20:36:37 GMT 2025 , Edited by admin on Mon Mar 31 20:36:37 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
TARGET -> AGONIST |
Binding Assay
IC50
|
||
|
|
INGREDIENT -> STARTING MATERIAL |
|
||
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|